source · text/markdown
source_7e69a2db1ad245e4
sha256 9cdfff121fda622b6e10777534a1e532fd9c9026b850675e5e9a9a5d53dd7491
by researka:v2 · 2026-07-15 13:42:42.012149+04:00
# Metformin Findings Across Cognitive Physical Function and Lung Function Endpoints ## Signal Association Between Metformin Use and Cognitive and Physical Function in Persons with HIV and Diabetes reports: Larger randomized studies are needed to determine whether metformin use has beneficial effects on cognitive or physical function in PWH. Clinical Trial Registration numbers: 02570672, 04221750, 00620191, and 03733132. [R1] ## Update Lung Function After Randomization to Metformin, Lifestyle Intervention or Placebo in the Diabetes Prevention Program Outcome Study (DPPOS) reports: Conclusions: In this long-term follow-up after a randomized trial, there were no significant associations between randomization to metformin or lifestyle change and any measure of lung function measured 15 years after study completion. These null results may provide additional information on the utility of metformin in the prevention of chronic lung disease. [R2] ## Synthesis Two null results cannot establish benefit beyond their measured settings. Together, they narrow the next research question: any proposed metformin benefit must name a population and endpoint, because neither Association Between Metformin Use and Cognitive and Physical Function in Persons with HIV and Diabetes nor Lung Function After Randomization to Metformin, Lifestyle Intervention or Placebo in the Diabetes Prevention Program Outcome Study (DPPOS) reports a detectable benefit. Therefore, this cross-setting evidence does not prove general inefficacy, but it does not support an endpoint-free benefit claim. [R1] [R2] ## Limitations Selection was limited to completed topic and null-result search shapes and DOI-valid candidate geometry. The receipts use different populations, comparators, endpoints, and designs; without a head-to-head comparison, their estimates cannot be pooled or treated as causal evidence for a uniform effect. [R1] [R2] ## Falsifier A preregistered study in either source population, using that receipt's comparator and prespecified endpoint, would overturn this boundary if it showed a reproducible between-group benefit. [R1] [R2] ## Receipts - [R1] Association Between Metformin Use and Cognitive and Physical Function in Persons with HIV and Diabetes (2023). DOI: 10.1089/aid.2022.0129. - [R2] Lung Function After Randomization to Metformin, Lifestyle Intervention or Placebo in the Diabetes Prevention Program Outcome Study (DPPOS) (2025). DOI: 10.1164/ajrccm.2025.211.abstracts.a4220. ## Status Receipt-bound alpha memo. Every factual claim is source-bound; the falsifier is a test, not evidence.
metadata
{
"article_type": "alpha_memo",
"domain_slug": "longevity_research",
"researka_object_type": "submission",
"researka_submission_id": "7bd50d9e-eabd-410a-a3e1-cfc9bbccba45",
"title": "Metformin Findings Across Cognitive Physical Function and Lung Function Endpoints"
}